Q-omics provides the consensus-scored RPL9P14 profile across patient tissues and cancer cell-line models. RPL9P14 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, RPL9P14 is differentially expressed in 8, with the highest sampling consensus in THCA. Additionally, RPL9P14 RNA expression shows 9,890 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight UVM, THCA, and TGCT as cancer lineages where RPL9P14 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL9P14 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL9P14 survival associations across molecular data types. RPL9P14 RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL9P14 RNA expression–survival associations across cancer types. High RPL9P14 expression shows unfavorable associations in UVM, THYM and READ, but favorable associations in HNSC, THCA and TGCT. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify UVM as the clearest survival context for RPL9P14 RNA expression.
This table summarizes RPL9P14 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for RPL9P14. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL9P14 shows lower tumor expression in THCA, KICH, UCEC, PAAD, READ and LUSC. The THCA box plot shows higher RPL9P14 RNA expression in normal versus tumor tissue (log2 FC = −0.330, t-test p < 0.001).
This table shows molecular features associated with RPL9P14 in patient tissues and cancer cell lines. In patient samples, RPL9P14 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
